Inka Health Publishes Framework to Enable Cross-Border Use of Real-World Evidence in Oncology
核心洞察
Inka Health (搜索), a subsidiary of Onco-Innovations, published a technical primer in the Journal of Clinical Evaluative Research addressing how to adapt medical evidence from one country for use in another through advanced statistical transportability methods.
The framework outlines three foundational principles for reliable cross-border evidence sharing: consistency, positivity, and conditional exchangeability, which will be integrated into Inka Health (搜索)'s AI-powered SynoGraph platform.
These transportability methods are particularly important for rare disease drug approvals where patient populations are small and local evidence is often lacking, potentially accelerating regulatory approvals and improving patient access to innovative therapies.
Inka Health (搜索) Corp., a subsidiary of Onco-Innovations Limited (搜索), has published a technical primer addressing a critical challenge in global healthcare decision-making: how to adapt medical evidence from one country for use in another. The publication, titled "Transportability of Non-Local Real-World Evidence and Its Relevance to Health Technology Assessment," appeared in the Journal of Clinical Evaluative Research and was co-authored with experts at AstraZeneca Canada (搜索).
The primer demonstrates how advanced statistical transportability methods can enable cross-border evidence sharing, with particular significance for rare disease drug approvals where patient populations are small and local evidence is often lacking. These methods have the potential to accelerate regulatory approvals and improve patient access to innovative therapies.
Framework for Cross-Border Evidence Sharing
The publication outlines three foundational principles required for reliable cross-border evidence sharing: consistency, positivity, and conditional exchangeability. By applying these "golden rules," global regulators, health technology assessment bodies, and industry stakeholders gain a practical framework to evaluate the relevance of non-local real-world evidence (RWE).
The article details proven statistical techniques including matching, weighting, standardization, and bias analysis that will be integrated into Inka Health (搜索)'s SynoGraph platform to address differences in patient populations. This integration ensures that real-world oncology data from various regions can be more confidently used to inform healthcare decisions worldwide.
Addressing Rare Disease Data Challenges
These approaches are especially important for rare disease drug approvals where patient populations are small and local evidence is often lacking. By enabling non-local data to be used effectively, the primer offers a potential solution to this bottleneck, ultimately helping to speed up approval and access to life-saving treatments.
"This primer marks a pivotal step toward making global health data more accessible and actionable," stated Paul Arora, Co-Founder of Inka Health (搜索). "By harnessing advanced statistical methods alongside AI-powered tools like SynoGraph, we can break down geographic barriers in oncology research. This publication is instrumental in exploring applications for transportability in real-world oncology settings and finding ways to help accelerate the delivery of innovative treatments to patients who need them most, particularly in rare disease communities where data scarcity has long been a challenge."
AI-Powered Platform Integration
By incorporating these transportability methods into SynoGraph, Inka Health (搜索) is advancing the use of artificial intelligence to overcome global data challenges in oncology, supporting more precise, timely, and evidence-based treatment decisions worldwide. The SynoGraph platform leverages AI-powered causal inference to identify which cancer patients are most likely to respond to specific treatments, advancing precision medicine through the integration of diverse multimodal medical data, including genomics, transcriptomics, and proteomics.
AstraZeneca Canada (搜索) became a client of Inka Health (搜索) on September 23, 2024, prior to Inka Health becoming part of Onco-Innovations on February 3, 2025. The collaboration focuses on real-world evidence and analytic methods publications being developed under their services agreement.